Volume 11 Supplement 1

Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection

Open Access

Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients

  • M Bickel1,
  • A Bodtlaender2,
  • G Knecht2,
  • M Kurowski3,
  • S Klauke2 and
  • T Lutz2
Journal of the International AIDS Society200811(Suppl 1):P59

DOI: 10.1186/1758-2652-11-S1-P59

Published: 10 November 2008

Background

In the past years, once-daily (QD) dosing of antiretroviral combination therapy has become an increasingly available treatment option for HIV-1+ patients.

Methods

Open label study in which HIV-1+ patients treated with SAQ/RTV (1000/100 mg BID) and two NRTIs with HIV-RNA-PCR < 50 copies/ml were switched to SAQ/RTV(2000/100 mg QD) with unchanged NRTI-backbone. CD4-cells, HIV-RNA-PCR, SAQ and RTV drug-levels and metabolic parameters were compared.

Summary of results

17 patients (15 male, 42 years), median CD4 456 ± 139/μl were included so far. The median follow-up time is 4 months. The HIV-RNA-PCR remained <50 copies/ml for all patients. Fasting metabolic parameters remained unchanged. The SAQ AUC 0–12 h were significantly higher when given QD vs. BID (median 29,400 vs. 18,500 ng*h/ml; p = 0.009), whereas the Cmin, Cmax and AUC was lower for RTV when given QD vs. BID (7,400 vs. 11,700 ng*h/ml; p = 0.02).

Conclusion

In this ongoing study SAQ/RTV (2000/100 mg QD) was well tolerated and demonstrated higher SAQ and lower RTV drug levels as compared to the BID dosing schedule. (Table 1 and Figure 1.)

Table 1

 

baseline

month 3

p-value

Glucose [mg/dl]

91 ± 12

91 ± 10

0.9

Triglycerides [mg/dl]

178 ± 106

161 ± 96

0.7

Total chol. [mg/dl]

199 ± 43

206 ± 46

0.8

HDL chol. [mg/dl]

43 ± 9

44 ± 8

0.8

LDL chol. [mg/dl]

131 ± 31

133 ± 33

0.6

Figure 1

SAQ drug level BID vs. QD.

Authors’ Affiliations

(1)
HIV Research and Treatment Unit
(2)
Infektiologikum
(3)
Therapia GmbH

Copyright

© Bickel et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement